Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07209326 in Healthy Participants and Sickle Cell Disease
NCT04255875Phase 1Completed
- Sponsor
- Pfizer
- Start
- Feb 2020
- Primary completion
- Jul 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07209326 in sickle cell anemia (SCA) (3 arms), sponsored by Pfizer. Primary endpoints: Treatment Emergent Adverse Events, Percentage of subjects with laboratory abnormalities and 4 more. Started Feb 2020; status: completed.
02
Drugs
PF-07209326
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT04255875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04255875.